Showing results (1-10 of 85) with videos related to
Sort By:
Pageof 9
Molecular & Cellular Oncology|November 7, 2019
Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancerPau Castel, Eneda ToskaNature Cancer|February 4, 2022
The present and future of PI3K inhibitors for cancer therapyPau Castel, Eneda Toska, Jeffrey A Engelman, et al.Molecular & Cellular Oncology|June 17, 2016
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentPau Castel, Eneda Toska, Zachary S Zumsteg, et al.Biochimica Et Biophysica Acta. Reviews on Cancer|March 22, 2024
Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancerEneda ToskaCancer Research|October 17, 2022
A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast CancerRyan Blawski, Eneda ToskaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Pharmacology in the Era of Targeted Therapies: The Case of PI3K InhibitorsEneda Toska, José BaselgaThe Journal of Pathology|September 9, 2025
Sparking malignancy: nicotine as a driver of stemness and metastasis in triple-negative breast cancer<sup>†</sup>Christopher Simpkins, Eneda ToskaFrontiers in Oncology|July 1, 2022
Epigenetic Mechanisms Influencing Therapeutic Response in Breast CancerAmaia Arruabarrena-Aristorena, Eneda ToskaTrends in Immunology|July 27, 2024
Mutant ARID1A: igniting cancer immunotherapyBujamin H Vokshi, Eneda ToskaMolecular & Cellular Oncology|May 24, 2021
<i>FOXA1</i> mutations influence the therapeutic response of breast cancer by altering chromatin stateAmaia Arruabarrena-Aristorena, Eneda ToskaPageof 9